Overview

Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)

Status:
Completed

Trial end date:
2015-09-11

Target enrollment:

Participant gender:

Summary

This is a multi-part study to evaluate the safety, tolerability, and pharmacokinetics (PK) of uprifosbuvir (MK-3682/IDX21437) in healthy participants and in participants infected with Hepatitis C virus (HCV) genotype (GT)1-GT6. The effect of food on the PK of uprifosbuvir will be evaluated. The antiviral activity of uprifosbuvir will also be assessed in HCV-infected participants.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Hydroxyitraconazole
Itraconazole
Uprifosbuvir